ClinicalTrials.gg
Not yet recruitingNCT06611332Updated Sep 24, 2024

Efficacy and Safety of Electroacupuncture on Lumbar Disc Herniation with Radiculopathy

An interventional study of Electroacupuncture and Sham electroacupuncture in Lumbar Disc Herniation and Radiculopathy Lumbar, sponsored by Jiangxi University of Traditional Chinese Medicine. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-09-24.

Sponsored by Jiangxi University of Traditional Chinese Medicine · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Lumbar disc herniation with radiculopathy (LDHR) is the local displacement of the intervertebral disc and its contents beyond the edge of the normal intervertebral disc space, resulting in pain, weakness or numbness in the muscle or dermatomal distribution area. Electroacupuncture is based on obtaining the needling sensation manually and applying electrical stimulation of different frequencies and intensities, aiming to enhance the intensity of acupoint stimulation to improve the effect. As a kind of acupoint stimulation therapy, electroacupuncture has shown analgesic effects in animal experiments. However, at present, the clinical evidence of electroacupuncture applied in the treatment of LDHR is still insufficient. Therefore, this randomized, single-blind, sham electroacupuncture controlled trial aims to evaluate the efficacy and safety of electroacupuncture as a treatment for LDHR.

02

Conditions studied

  • Lumbar Disc Herniation
  • Radiculopathy Lumbar

Keywords

  • electroacupuncture
  • radiculopathy
  • sham control
  • randomized controlled trial
  • lumbar disc herniation
03

In context

Intervertebral Disc Displacement

474 studies on the registry are indexed under Intervertebral Disc Displacement; 100 are open to participants now.

This study's planned enrollment of 170 is above the median of 63 across 344 interventional studies indexed under Intervertebral Disc Displacement.

Browse Intervertebral Disc Displacement studies →

Lead sponsor

Jiangxi University of Traditional Chinese Medicine is the lead sponsor of 15 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged from 18 to 70 years old.
  2. With intervertebral disc protrusion confirmed by a MRI or CT, accompanied by radicular pain in the lower extremities.
  3. With a NRS score ≥ 4 points for both low back pain and leg pain, and the pain lasts for at least 3 months;
  4. Voluntarily participating the trial and signing the form.

Exclusion criteria

Exclusion Criteria:

  1. Previous surgical treatment of the spine.
  2. Received any physical therapy for lumbar disc herniation within the recent 3 months.
  3. Complicated with diseases that can cause low back and leg pain.
  4. Symptomatic foraminal stenosis caused by severe degenerative diseases, accompanied by severe nerve injuries.
  5. Previous severe mental illness, organ failure, or malignant tumor.
  6. Planned spinal surgery or other major surgeries within the next 3 months.
  7. Pregnancy or lactation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
170 participants (estimated)

Study arms

  • Experimental
    Electroacupuncture

    Other: Electroacupuncture

  • Sham comparator
    Sham electroacupuncture

    Other: Sham electroacupuncture

Interventions

  • OtherElectroacupuncture

    The main acupoints selected for the electroacupuncture group are bilateral BL23, bilateral BL25, bilateral GB30, bilateral LR11, bilateral LR8, GV4, GV3, and the affected BL40, and the secondary acupoints selected are bilateral BL54, the affected side BL57 and the affected side BL60.The treatment will be administered once every other day for 30 minutes each time, lasting for 8 consecutive weeks, totaling 24 sessions.

  • OtherSham electroacupuncture

    In the sham electroacupuncture group, the acupoints will be at a position 2 cm lateral to the correct acupoints horizontally. The dosage and treatment course are the same as those in the electroacupuncture group.

06

What researchers measure

Primary outcomes

  1. Proportion of responders

    Definition of a response: a reduction of at least 2 points in the score of the Numerical Rating Scale for both low back pain and leg pain.

    Time frame: Weeks 8 and 24

Secondary outcomes

  1. Intensity of low back pain

    Changes from baseline in the intensity of low back pain assessed by the Numerical Rating Scale

    Time frame: Weeks 2, 4, 8, 16, and 24

  2. Intensity of leg pain

    Changes from baseline in intensity of leg pain assessed by the Numerical Rating Scale

    Time frame: Weeks 2, 4, 8, 16, and 24

  3. Level of disability

    Changes from baseline in the level of disability assessed by the Roland-Morris Disability Questionnaire

    Time frame: Weeks 2, 4, 8, 16, and 24

  4. Performance status

    Changes from baseline in functional status assessed by the Japanese Orthopaedic Association Score

    Time frame: Weeks 2, 4, 8, 16, and 24

  5. Severity of depression

    Changes from baseline in the severity of depression assessed by the Hamilton Depression Rating Scale

    Time frame: Weeks 2, 4, 8, 16, and 24

  6. Severity of anxiety

    Changes from baseline in the severity of anxiety assessed by the Hamilton Anxiety Rating Scale

    Time frame: Weeks 2, 4, 8, 16, and 24

  7. Sleep quality

    Changes from baseline in sleep quality assessed by the Insomnia Severity Index

    Time frame: Weeks 2, 4, 8, 16, and 24

  8. Pain self-efficacy

    Changes from baseline in pain self-efficacy assessed by the Pain self-efficacy questionnaire

    Time frame: Weeks 2, 4, 8, 16, and 24

  9. Use of analgesics

    The proportion of patients who used analgesics for emergency.

    Time frame: Weeks 8 and 24

  10. Incidence of lumbar spine surgery

    The incidence of lumbar spine surgery during the follow-up

    Time frame: Weeks 8 and 24

  11. Incidence of any adverse events

    Adverse events be reported by patients and determined by clinicians.

    Time frame: Weeks 8 and 24

  12. Incidence of treatment-related adverse events

    Treatment-related adverse events include adverse events caused by electroacupuncture or sham electroacupuncture treatment.

    Time frame: Weeks 8 and 24

  13. Incidence of serious adverse event

    Serious adverse events refer to adverse events that require hospitalization or an extended hospital stay, result in disability, pose a threat to life, or cause death.

    Time frame: Weeks 8 and 24

07

Study locations

1 site
  • The Affiliated Hospital of Jiangxi University of Chinese Medicine
    Jiangxi, Nanchang 330006, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2024; primary completion for Oct 2025, 12 months later.

Of 178 non-industry interventional studies with no phase under Intervertebral Disc Displacement, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 12 months is close to that.

Counting every sponsor, half of 191 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2024
First posted
Sep 24, 2024
StartEst.
Oct 15, 2024
Primary completionEst.
Oct 15, 2025
CompletionEst.
Oct 25, 2025
Last update
Sep 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06611332
Lead sponsor
Jiangxi University of Traditional Chinese Medicine
Responsible party
Xu Zhou (Professor, Jiangxi University of Traditional Chinese Medicine) — Principal investigator
First posted
Sep 24, 2024
Start date
Oct 15, 2024 (estimated)
Primary completion
Oct 15, 2025 (estimated)
Completion
Oct 25, 2025 (estimated)
Last update
Sep 24, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion